⌘K

Home/Filings/4/0001493152-22-036727

4//SEC Filing

Huntsman Ronald Kirk 4

Accession 0001493152-22-036727

CIK 0001716166other

View on SEC.gov Company Profile

Filed

Dec 27, 7:00 PM ET

Accepted

Dec 28, 9:45 PM ET

Size

10.1 KB

Accession

0001493152-22-036727

Insider Transaction Report

Form 4

Period: 2022-12-23

Vivos Therapeutics, Inc.VVOS

Huntsman Ronald Kirk

DirectorChief Executive Officer10% Owner

Transactions

Award
Stock Option (Right to Buy)
2022-12-23$0.48/sh+150,000$72,000→ 483,334 total
Exercise: $0.48Exp: 2027-12-23→ Common Stock (483,334 underlying)
Purchase
Common Stock
2022-12-23$0.50/sh+20,000$10,000→ 47,500 total
Award
Stock Option (Right to Buy)
2022-12-23$0.48/sh+333,334$160,000→ 333,334 total
Exercise: $0.48Exp: 2027-12-23→ Common Stock (333,334 underlying)

Holdings

Common Stock
(indirect: See footnote)
1,740,000

Footnotes (3)

[F1]Shares held by Coronado V Partners, LLC, of which the reporting person is a member and manager.
[F2]333,334 fully vested stock options granted on December 23, 2022.
[F3]150,000 stock options granted on December 23, 2022. One-fifth vested immediately and one-fifth vests annually on each anniversary date through December 23, 2026.

Documents

1 file

4
ownership.xmlPrimary

Issuer

Vivos Therapeutics, Inc.

CIK 0001716166

Entity typeother

Related Parties

1

filerCIK 0001835498

Filing Metadata

Form type: 4
Filed: Dec 27, 7:00 PM ET
Accepted: Dec 28, 9:45 PM ET
Size: 10.1 KB

View on SEC.gov